Last reviewed · How we verify
basal bolus insulin therapy
Basal bolus insulin therapy replaces the body's natural insulin secretion by providing a long-acting basal insulin dose once or twice daily plus rapid-acting bolus insulin doses with meals to control blood glucose.
Basal bolus insulin therapy replaces the body's natural insulin secretion by providing a long-acting basal insulin dose once or twice daily plus rapid-acting bolus insulin doses with meals to control blood glucose. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when other agents insufficient).
At a glance
| Generic name | basal bolus insulin therapy |
|---|---|
| Sponsor | Consorci Sanitari Integral |
| Drug class | Insulin therapy |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This regimen mimics physiological insulin secretion by combining a steady background (basal) insulin level with meal-time (bolus) insulin injections. The basal component suppresses hepatic glucose production between meals and overnight, while bolus doses control postprandial glucose spikes. Both components work by binding to insulin receptors on muscle and adipose tissue to promote glucose uptake and utilization.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when other agents insufficient)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes (NA)
- SHOrt-term Glycemic Control for Reducing Post-SURGical Complications (NA)
- App-Based Certified Diabetes Education Therapy (AB-CDE) (NA)
- Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes" (PHASE3)
- Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control (NA)
- Accuracy of a Continuous Ketone Monitoring (CKM) System in Individuals With Type 1 Diabetes on Insulin Pump Therapy.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- basal bolus insulin therapy CI brief — competitive landscape report
- basal bolus insulin therapy updates RSS · CI watch RSS
- Consorci Sanitari Integral portfolio CI